Author Index

VOLUME 28, 2002

Adachi, Tomoko, 525
Agnelli, Giancarlo, S2:33
Alban, Susanne, 369
Alikhan, Raza, 569
Amirkhosravi, Ali, 29
Ananyeva, Natalya M., 309
Anderson, Frederick A. Jr., S3:43
Andersen, Judith C., 79
Asayama, Kohtaro, 539
Auer, Wilfried, 215
Auerswald, Günter, 203, S1:57

Barrowcliffe, Trevor W., 247
Bauer, Kenneth A., S2:15
Bauersachs, Rupert, 439
Becker, Sabine, S1:57
Bergmann, Frauke, 227
Bergmann, Jean-François, S3:51
Bergqvist, David, S3:19
Berneman, Zwi, 111
Bisio, Antonella, 325
Bode, Christoph, 459
Borggrefe, Martin, 483
Bouthier, Jean, 393
Branellec, Jean-François, 393
Brinkhous, Kenneth, 269
Brückmann, Martina, 483
Brugarolas, Antonio, 5
Bruno, Cristiana, 383
Budde, Ulrich, 173, 227
Budek, Irmhild, 139
Büller, Harry R., S2:1, S2:41, S2:49

Caiafa, Jackson S., S3:47
Cariou, Roger, 393
Casella, Nicola, 383
Casu, Benito, 325, 343
Cauwenberghs, Nancy, 161
Cohen, Alexander T., S3:13
Cohen, Ander, 569
Cosgrove, Richard H., 79

D'Alessandro-Gabazza, Corina N., 5
Davidson, Bruce L., S3:41, S3:51
de Bastos, Marcos, S3:47
Deckmyn, Hans, 161
de Groot, Philip G., 133
Donat, François, 393
Dorner, Friedrich, 215
Dossi, Carla, 383
Drewke, Elke,173
Duc, Gérald, 393
Duchaussoy, Philippe, 393

Eberspächer, Bruno, 203
El Hajji, Mohamed, 393
Engl, Werner, 203
Ettingshausen, Carmen Escuriola, 285

Falger, Jutta, S1:63
Favaloro, Emmanual J., 191
Fenyvesi, Tivadar, 361, 379
Fischer, Karl-Georg, 403, 467, 483
Francis, John L., 29
Fujimoto, Seiichiro, 501, 507
Fukushima, Shinji, 539
Furlan, Miha, 167

Gabazza, Esteban C., 5
Gardner, Jeremy, 569
Garrigou, Eric, 393
Göeser, Tobias, S1:37
Goy, Christine, 139
Greer, Ian A., S3:25
Greinacher, Andreas, 431
Gritsch, Herbert, 215
Gröner, Albrecht, S1:79
Guerrini, Marco, 325, 343
Güertler, Lutz, S1:31
Güthner, Christiane, 203

Haas, Sylvia K., 577
Haase, Karl Konstantin, 483
Hafner, Gerd, 425
Harenberg, Job, 343, 361, 379
Hashiguchi, Kazunari, 525
Hassouna, Houria I., 89
Hata, Akira, 501, 507
Hauser, Charlotte A.E., 309
Heimburger, Norbert, S1:25
Heit, John A., S2:3, S3:33
Hemker, H. Coenraad, 369
Herbert, Jean-Marc, 393
Hirai, Makoto, 545
Hricovíni, Milos, 325
Hubbard, Anthony R., 247
Huhle, Günter,483
Huth-Küehne, Angela, S1:75

Ito, Masafumi, 545

Jörg, Ingrid, 361, 379

Kakkar, Ajay K., S3:1, S3:57
Kanayama, Naohiro, 495, 511, 533
Kemkes-Matthes, Bettina, 455
Khushal, Amjad, 569
Klarmann, Dieter, S1:57
Klinge, Jens, 309
Klingebiel, Thomas, 285
Kobashi, Gen, 501, 507
Kobayashi, Takao, 495, 511, 533
Kojima, Tetsuhito, 545
Koksch, Marie, 203
Kommareddy, Aruna, 89
Kondo, Kiyotaro, 501, 507
Kondo, Takahisa, 545
Kreuz, Wolfhart, 203, 285, S1:57
Kröniger, Arno, S1:57
Kurnik, Karin, S1:57
Kurnik, Peter, S1:63

Lämmle, Bernhard, 167
Lee, Christine, 241
Lendemans, Sven, S1:87
Lenk, Harald, S1:51
Liebe, Volker, 483
Leithäuser, Boris, S1:87
Lindhoff-Last, Edelgard, 439
Liu, Dongfang, 67
Loskutoff, David J., 545
Lubenow, Norbert, 431
Lucatello, Lorena, 355
Lusher, Jeanne M., 273

Maeda, Makato, 533
Mainusch, Kerstin, 173

Note: Numbers preceded by S1 indicate pages in Volume 28, Supplement 1; S2 indicates pages in Volume 28, Supplement 2; and S3 indicates pages in Volume 28, Supplement 3.

Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Male, Christoph, S1:63
Malsch, Reinhard, 343
Mammen, Eberhard F., 1, 109, 239, 323, 491, S1:1
Markwardt, Fritz, 405
Matsubara, Shigeki, 519
Matsuda, Yoshio, 525
Matsuno, Kazuhiko, 529
Matsuo, Osamu, 529
Matsushita, Tadashi, 545
Matsuyama, Kaoru, 533
Matthias, F. Reinhard, S1:87
Meehan, Kenneth R., 19
Michiels, Jan J., 111, 227
Mikaelsson, Marianne, 257, 269
Minakami, Hisanori, 515, 519
Mitterer, Artur, 215
Moriyama, Takanori, 529
Mouly, Stéphane, S3:51
Moura, L.K., S3:47
Mousa, Shaker A., 45
Muchitsch, Eva-Maria, 215
Muntean, Wolfgang, S1:63
Murohara, Toyoaki, 545

Nabeshima, Yoichi, 545
Naggi, Annamaria, 325, 343, 355, 383
Nakada, Marian T., 39
Naruse, Hiroo, 511
Nauck, Matthias, 425
Necciari, José, 393
Neugebauer, Brigitte M., 139
Nichols, Timothy, 269
Nimtz, Antje, 203
Nishiguchi, Tomizo, 495, 511, 533
Nishimura, Masahiko, 545
Nowak, Götz, 415
Nowak, Thomas, S1:79

Ohkuchi, Akihide, 519
Ohta, Hiroaki, 525
Ohta, Kaori, 501, 507
Okada, Kiyotaka, 529
Oldenburg, Johannes, 285
Onagawa, Tamaho, 519
Ornstein, Deborah L., 5, 19
Oswaldsson, Ulla, 257, 269

Palumbo, Manlio, 355
Petitou, Maurice, 393
Piazolo, Lukas, 343, 379
Pichler, Ludwig, 215
Pindur, Gerhard, 203
Poggi, Andreina, 383
Pollmann, Hartmut, S1:47

Qi, Yiwei, 67
Quinlan, Dan, 569

Racine, Eric, 79
Raut, Sunjeev, 247
Raymond, S., S3:47
Read, Marjorie, 269
Richter, Hendrick, S1:47
Römisch, Jürgen, S1:79
Roser, Markus, 425
Rossi, Cosmo, 383

Saenko, Evgueni L., 309
Saguer, Immaculada Martinez, 285
Saint-Remy, Jean-Marie R., 265
Saito, Hidehiko, 545
Sakata, Yoichi, 519
Samama, Meyer-Michel, S3:1, S3:57
Sands, Dawn, 247
Sandberg, Helena, 269
Sane, David C., 555
Sasisekharan, Ram, 67
Sato, Ikuo, 519
Sato, Telsuji, 539
Scandella, Dorothea, 291
Scharrer, Inge, S1:7
Schaub, Robert G., 269
Scheel, Horst, 203
Schimpf, Klaus, S1:15
Schlokat, Uwe, 215
Schmitt, Klaus, S1:63
Schneider, Jeffrey, 5
Schneider, Marion, S1:51
Schneppenheim, Reinhard, 173
Schreiber, Jörg D., 203
Schroyens, Wilfried, 111
Schumacher, Johannes, S1:87
Schwarz, Hans Peter, 149, 215
Schwarz, Rudolf, S1:63
Seitz, Rainer, 139
Severin, Thomas, 447
Shido, Koichi, 501, 507
Shirahata, Akira, 539
Shirakawa, Yoshitsugu, 539
Shriver, Zachary, 67
Siekmann, Jürgen, 149, 203
Sigman, Jeffrey, 269
Sissi, Claudia, 355
Sjöberg, Katarina, 297
Streif, Werner, S1:63
Sturiale, Luisella, 383
Sugimura, Motoi, 495, 511
Suiter, Tobias M., 277
Sumimoto, Kazuhiro, 495
Sutor, Anton H., 403, 447, 529, S1:9
Suzuki, Shigenori, 515, 529

Takeshita, Kyosuke, 546
Tanaka, Toshirou, 539
Terao, Toshihiko, 495, 511
Tillmanns, Harold, S1:87
Tokunaga, Naoki, 495, 511
Torri, Giangiacomo, 335, 343, 355
Trikha, Mohit, 39
Turecek, Peter L., 149, 203, 215
Turpie, Alexander G.G., S2:1, S2:25, S2:49

Uhle, Christian, S1:75

Vandecasteele, Griet, 161
van de Loo, Andreas, 459
van der Planken, Marc, 111
van de Velde, Ann, 111
Vanhoorelbeke, Karen, 161
van Vliet, Huub H.D.M., 111
Váradi, Katalin, 215
Varki, Ajit, 53
Varki, Nissi M., 53
Vauterin, Stephan, 161
Venkataraman, Ganesh, 67

Wada, Tomoaki, 51s9
Wank, Johann, S1:63
Watanabe, Takashi, 519
Welzel, Dieter, 369
White, Kami, S3:45
Widlund, Lars, 269
Wikén, Margareta, 297
Wilkerson, Wade, 555
Wolf, Hans-Heinrich, 203

Yamada, Hideto, 501, 507, 515
Yamamoto, Koji, 539
Yamashita, Miwa, 533

Zacharski, Leo R., 5, 19, 79
Zaroukian, Michael H., 89
Zenz, Werner, S1:63
Zieger, Barabra, 447
Zimmermann, Rainer, S1:75
Zokai, Kawei, 379
Zwiauer, Karl, S1:63
Zyschka, Alex, 285

Subject Index

VOLUME 28, 2002

A
Activated partial thromboplastin time
  monitoring of anticoagulant effects of thrombin inhibitors and, 361
  as screening test for von Willebrand disease, 173
  in von Willebrand disease, Immunate treatment and, 203
Active-site inhibitors, S2:15
Acute fatty liver of pregnancy, gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to development of, 515
Acute renal failure, hirudin in, 467
Adolescents, pharmacosurveillance investigation of safety of pasteurized clotting factor concentrates in, S1:63
Aging
  increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of, 545
  thrombosis and, 555
Angina, unstable
  antiplatelet drugs for, S3:3
  direct thrombin inhibitors in, 459
Angiogenesis
  antiangiogenic therapy and, 39
  anticoagulant interference with, 45
  blood coagulation and, 29
  low molecular weight heparin inhibition of, 79
  thrombosis and, aging and, 555
Angiotensinogen gene, for hypertension prevention in pregnancy, 501
Anticoagulants. *See also specific anticoagulants*
  conventional, S2:15
  effects on tumor dissemination, 29
  in glioma treatment, S1:19
  heparan sulfate-like glycosaminoglycans as, 67
  during lactation, 439
  monitoring of anticoagulant effects of thrombin inhibitors and, 361
  during pregnancy, 439
  selective inhibition of coagulation factors and, S2:15
  survival of cancer patients with thromboembolic diseases and, 45
  target-specific, S2:15
  von Willebrand disease during therapy with, 227
Antihemostatic agents, effects on tumor dissemination, 29
Antiplatelet agents
  antiangiogenic activity of, 39
  effects on tumor dissemination, 29
  for venous thromboembolism, review of, S3:3
Anti-recombinant hirudin antibodies, in vitro and in vivo studies of, 483
Antistasin, S2:15
Antithrombin, S2:15
  activity of
    to distinguish preeclampsia from normal pregnancy, 495
    plasma, perioperative changes in patients undergoing gynecologic surgery, 519
  calcium ion effects on interactions between antithrombin and factor Xa mediated by low molecular weight heparin and, 355
  heparin pentasaccharide bound to, conformation of, 325
  pasteurized concentrate of, purity, activity, and virus safety of, S1:79
  pregnancy-induced deficiency of, as progenitor to HELLP syndrome, 515
  selective inhibition of factor Xa by synthetic pentasaccharides and, 393
Antithrombotic therapy. *See also* Venous thromboembolism; *specific agents*
  benefits of selective factor inhibition for, S2:49
  future challenges in use of, S3:33
  improving outcomes of treatment of symptomatic venous thromboembolism and, S2:41
  new agents for, S3:33
  new standards in, overview of, S2:1
  optimization of venous thromboembolism prophylaxis, S2:25
  prolonged, in orthopedic surgery, S3:43
  review of, S3:3
  selective inhibition of coagulation factors and, S2:15
  timing of therapy using, S3:33
  unresolved issues in venous thromboembolism prevention and treatment and, S2:33
  venous thromboembolism epidemiology and, S2:3
Aortic stenosis, von Willebrand disease with, 227
Argatroban
  for heparin-induced thrombocytopenia, 431
  monitoring of anticoagulant effects of thrombin inhibitors and, 361
Aspartate aminotransferase, gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to HELLP syndrome and, 515

Note: Numbers preceded by S1 indicate pages in Volume 28, Supplement 1; S2 indicates pages in Volume 28, Supplement 2; and S3 indicates pages in Volume 28, Supplement 3.

Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Atherosclerosis, von Willebrand disease with, 227
Autocrine signaling loops, heparan sulfate-like glycosaminoglycans in, 67

B
Baby hamster killer cells, for recombinant factor VIII production, 277
Basic fibroblast growth factor, heparin binding to, 45
Beriate HS, S1:25
Bivalirudin, S2:15
Bleeding disorders. *See also specific disorders*
von Willebrand factor role in platelet function and, S1:33
Bleeding time
as screening test for von Willebrand disease, 173
von Willebrand factor response to desmopressin and, 111
Blood-borne viruses. *See also* Hepatitis viruses
transmission during hemophilia treatment, S1:31
Body mass index
for hypertension prevention in pregnancy, 501
preeclampsia association with maternal smoking in Japanese women and, 507
Bothrocetin-induced agglutination, for von Willebrand factor, 173
Brain embolism, paradoxical, in pregnancy, 525
Breast milk. *See* Lactation

C
Calcium ion, effects on interactions between antithrombin and factor Xa mediated by low molecular weight heparin, 355
Cancer. *See* Malignancies
Carcinoma, heparin inhibition of selectin-mediated interactions during hematogenous phase of metastasis of, 53
Cardiovascular diseases. *See also specific diseases*
thromboprophylaxis in, S3:51
von Willebrand disease with, 227
Cardiovascular system, age-related alterations in, 555
Carinactivase-1 method, prothrombin levels by, in newborn infants, 539
Cell adhesion, heparan sulfate-like glycosaminoglycans in, 67
Cell growth, low molecular weight heparin inhibition of, 79
Central venous catheterization, upper extremity deep vein thrombosis and, 89
Children. *See* Pediatric patients
Chromogenic assay, for monitoring direct thrombin inhibitors, 425
Cirrhosis, of liver, with hepatitis, S1:31
Clotting factor concentrates. *See also specific factors*
pasteurized. *See* Pasteurized clotting factor concentrates
virus-inactivated, in severe hemophilia, S1:75
virus-safe, S1:15
Clotting time, monitoring of anticoagulant effects of thrombin inhibitors and, 361
Coagulation index, to distinguish preeclampsia from normal pregnancy, 495
Coagulation system
as target for treatment of human gliomas, S1:19
thrombosis and, aging and, 555
Collagen, von Willebrand factor binding to, 111
Collagen-binding assays for von Willebrand factor, 173
comparison of, 139
experience with, 191
ristocetin cofactor activity assay compared with, 149
Coronary ischemic syndromes, hirudin for, 405
Coronary syndromes, acute
antithrombotic therapy for, review of, S3:3
future challenges for management of, S3:33
hirudin for, 459
Coumadin, effects on tumor dissemination, 29
Cryoprecipitate
infectious and noninfectious side effects during hemophilia treatment using, S1:51
as starting material for coagulation factor concentrates, S1:25

D
Danaparoid
chemistry, pharmacology, and pharmacokinetics of, 439
for heparin-induced thrombocytopenia, 431
in pregnancy and lactation, 439
in pediatric patients, 447
Deep vein thrombosis. *See also* Venous thromboembolism
anticoagulants and survival of patients with, 45
epidemiology of, prevention and management implications of, S2:3
hirudin for prophylaxis and treatment of, 455
in hospitalized medical patients, risk and prevention of, 577
optimization of venous thromboembolism prophylaxis and, S2:25
in surgery for malignancies, rationale for prolonged thromboprophylaxis and, 569
of upper extremity, 89
Dermatan sulfate, end-group labeled with tyramine and fluorescein, study of biological functions and pharmacology using, 343
Desmopressin, von Willebrand factor response to, in patients with type 1 and type 2 congenital von Willebrand disease, 111
Direct thrombin inhibitors, inhibitors of, S2:33
Disseminated intravascular coagulation
in cancer, 39
hirudin for, 405
DX-9065a, S2:15

E
Ecarin clotting time
for monitoring direct thrombin inhibitors, 425
monitoring of anticoagulant effects of thrombin inhibitors and, 361
Eclampsia. *See also* Preeclampsia
seizures in, anticholinergic induction of, 511
Elderly people
increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
thrombosis and aging and, 555
Endocarditis, von Willebrand disease with, 227
Endotoxin, antithrombin attenuation of microvascular leakage and leukocyte-endothelial interaction in response to, S1:87
End-stage renal disease, hirudin in, 467
Enoxaparin
in pregnancy, S3:25

for thromboprophylaxis in medical patients, in France, S3:51
for thrombosis care for medical patients, S3:13
Enzyme-linked immunosorbent assay
for von Willebrand factor, 139
epitope-specific, 173
for von Willebrand factor: ristocetin cofactor assay, 149
Enzyme systems, low molecular weight heparin effects on, 79
Extracellular matrix
treatment of malignancies by plasminogen activation and, 5
tumor growth and metastasis regulation by heparan sulfate-like glycosaminoglycans of, 67
Extracorporeal blood purification, for removing hirudin from circulation, 467
Extracorporeal circulation, hirudin use with, 405

F
Factor concentrates, efficacy of, assessment of, 191
Factor VIIa-tissue factor inhibitors, unresolved issues in venous thromboembolism prevention and treatment and, S2:33
Factor VIII
activity of
coagulation and chromogenic assays of, 247
in von Willebrand disease, Immunate treatment and, 203
anti-SQ-peptide specific antibodies in patients treated with ReFacto and, 297
assay methods for, 247
activity and antigen measurements compared and, 257
one-stage and chromogenic assay results compared and, 257
"physiological" clotting assays and, 257
product-specific standards for, 257
variations among laboratories in, 247
in circulation, role of von Willebrand factor in preserving, 215
collagen-binding assays for von Willebrand factor in, 139
interactions in intrinsic pathway, 309
plasma-derived, recombinant factor VIII versus, in previously untreated patients, 285
recombinant. *See* Recombinant factor VIII
safety and efficacy of, 309
structure and function in hemostasis, 309
Factor VIII inhibitors
antibody epitopes and, 285
anti-SQ-peptide specific antibodies in patients treated with ReFacto and, 297
clinical manifestations, diagnosis, and therapeutic options with, 309
development in previously untreated hemophilia A patients, plasma-derived versus recombinant factor VIII and, 285
epitopes of, 309
immunology of, 265
mechanisms of factor VIII inactivation by, 309
unusual responses to factor VIII and, 285
Factor Xa, calcium ion effects on interactions between antithrombin and factor Xa mediated by low molecular weight heparin and, 355
Factor Xa inhibitors
improving outcomes of treatment of symptomatic venous thromboembolism and, S2:41
indirect, S3:33
selective, S2:15, 393. *See also* Fondaparinux
unresolved issues in venous thromboembolism prevention and treatment and, S2:33
Fatty liver of pregnancy, gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to development of, 515
Fibrin degradation products D-dimer, to distinguish preeclampsia from normal pregnancy, 495
Fibrin formation, inhibition by direct thrombin inhibitors, 379
Fibrinolysis, S2:15
increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
thrombosis and, aging and, 555
treatment of malignancies by plasminogen activation and, 5
Fibroblast growth factors, conformation of heparin tetrasaccharides bound to, 325
Fluorescein, low molecular weight heparin and dermatan sulfate labeled with, study of biological functions and pharmacology using, 343
5-Fluorouracil, in proliferative vitreoretinopathy, 45
Fondaparinux
improving outcomes of treatment of symptomatic venous thromboembolism and, S2:41
optimization of venous thromboembolism prophylaxis and, S2:25
selective inhibition of coagulation factors and, S2:15
of factor Xa, 393

G
Gene expression, increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
Gene therapy, for hemophilia A, 309
Genetics, tree-based analysis of lifestyle risks for hypertension in pregnancy, 501
Geriatrics
increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
thrombosis and aging and, 555
Gestational thrombocytopenia, as progenitor to HELLP syndrome, 515
Gliomas, coagulation system as target for treatment of, S1:19
Glycoprotein receptors, von Willebrand factor role in platelet function and, S1:33
Glycosaminoglycans. *See also* Dermatan sulfate; Heparin; Low molecular weight heparin
active conformations of, NMR determination of, 325
derivatives of, protein binding and biological properties of, 335
structure-activity relationships of, chemical derivatization for study of, 335
sulfation patterns of
controlled O-desulfation to generate sulfation gaps and glycol splitting, 335
modulation through regiospecific sulfation and desulfation, 335
Gynecologic surgery, perioperative changes in plasma

antithrombin activity and platelet counts in patients undergoing, 519

H
Haemate, S1:25
Haemate HS, S1:25
HELLP syndrome
gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to, 515
seizures in, anticholinergic induction of, 511
Hemodialysis, hirudin use with, 405, 467
Hemolytic-uremic syndrome, von Willebrand factor-cleaving protease assays in, 167
Hemophilia, virus safety of treatment for. *See* Virus safety of hemophilia treatment
Hemophilia A
antifactor VIII antibodies in. *See* Factor VIII inhibitors
clinical presentations of, 309
gene therapy for, 309
inhibitory antibodies produced in, 265
preclinical studies of albumin-free B-domain deleted recombinant factor VIII in, 269
previously untreated patients with
first and second generation recombinant factor VIII in, 277
inhibitor development in, 285
recombinant factor VIII activity in, 257
recombinant factor VIII for. *See* Recombinant factor VIII
Hemostasis
antiangiogenesis agents in, 45
overview of, S2:15
during pregnancy, plasminogen activator influence on onset of, 529
von Willebrand factor role in platelet function and, S1:33
Hepaplastin test, improvement of vitamin K status of breastfeeding infants with maternal supplementation of vitamin K2 and, 533
Heparan sulfate-like glycosaminoglycans, tumor growth and metastasis regulation by, 67
Heparin
B16-BL6 melanoma inhibition by semisynthetic sulfaminoheparosan sulfates from *E.coli* K5 polysaccharide and, 379
binding to angiogenic growth factors, 45
heterogeneity of preparations of, 53
inhibition of selectin-mediated interactions during hematogenous phase of metastasis by, 53
medium-molecular-weight, pharmacokinetics and pharmacodynamics of, 369
to prevent metastasis, 53
selective inhibition of coagulation factors and, S2:15
thrombocytopenia induced by
hirudin for, 405, 431
in pediatric patients, 447
in pregnancy and lactation, danaparoid for, 439
timing of treatment with, for metastasis prevention, 53
unfractionated, S2:15
improving outcomes of treatment of symptomatic venous thromboembolism and, S2:41
medium-molecular-weight heparin compared with, 369
use in cancer, 79
survival of cancer patients with thromboembolic diseases and, 45
unresolved issues in venous thromboembolism prevention and treatment and, S2:33
Heparin affinity chromatography for von Willebrand factor, 149
von Willebrand factor multimer analysis after separation by, 139
Heparin pentasaccharide, bound to antithrombin, conformation of, 325
Heparin tetrasaccharides, bound to fibroblast growth factors, conformation of, 325
Hepatitis viruses
clinical aspects of, S1:37
inactivation of, S1:31
pasteurized clotting factor concentrates in children and adolescents and, S1:63
safety of pasteurized clotting factor concentrates and, S1:57
transmission during hemophilia treatment, S1:31
treatment for, S1:37
virus-inactivated clotting factor concentrates in severe hemophilia and, S1:75
Hirudin, S2:15
for acute coronary syndromes, 459
chemical structure of, 415
for deep vein thrombosis prophylaxis and treatment, 455
for heparin-induced thrombocytopenia, 405, 431
in pediatric patients, 447
in pregnancy and lactation, 439
historical review of, 405
monitoring methods for, 425
monitoring of anticoagulant effects of thrombin inhibitors and, 361
recombinant. *See* Recombinant hirudin
in renal insufficiency, 467
therapeutic drug monitoring of, 415
toxicology of, 415
Human immunodeficiency virus infection, hepatitis in, S1:31
Hypertension
in pregnancy. *See also* Preeclampsia
prevention of, angiotensinogen gene and body mass index for, 501
pulmonary, von Willebrand disease with, 227

I
Immunate, for von Willebrand disease treatment, 203
Immune surveillance, platelet protection of tumor cells from, 39
Immune tolerance, to factor VIII, 265
Immunocompetence, prevention of metastasis and, 53
Immunologic diseases, von Willebrand disease with, 227
Immunosuppressed patients, hepatitis in, S1:31
Infants
improvement of vitamin K status of breastfeeding infants with maternal supplementation of vitamin K2 and, 533
newborn, prothrombin levels in, by carinactivase-1 method, 539
Inflammation, thrombosis and, aging and, 555

Inhibitor antibodies. *See specific inhibitors*
Interferons, for hepatitis treatment, S1:31

J
Joint bleeding, in hemophilia A, 309

K
Kybernin P, purity, activity, and virus safety of, S1:79

L
Labor, plasminogen activator influence on onset of, 529
Lactation
  heparin-induced thrombocytopenia in, danaparoid for, 439
  improvement of vitamin K status of breastfeeding infants with maternal supplementation of vitamin K2 and, 533
Leeches, hirudin from, 405
Lefaxin, S2:15
Lepirudin, for heparin-induced thrombocytopenia, 431
Leukocytes
  adhesion of, antithrombin attenuation of microvascular leakage and leukocyte-endothelial interaction in response to endotoxin and, S1:87
  metastasis and, 53
Lipoprotein receptor-related protein, animal studies of recombinant von Willebrand factor and, 215
Liver cirrhosis, with hepatitis, S1:31
Liver dysfunction, gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to HELLP syndrome and, 515
Liver transplantation, for hepatitis, S1:31
Low molecular weight heparin, S2:15
  antithrombotic potency of, direct thrombin inhibitors compared with, 379
  calcium ion effects on interactions between antithrombin and factor Xa mediated by, 355
  in cancer surgery, 569
  displacement by other glycosaminoglycans, 343
  effects on tumor dissemination, 29
  end-group labeled with tyramine and fluorescein, study of biological functions and pharmacology using, 343
  in glioma treatment, S1:19
  improved cancer mortality with, 79
  improving outcomes of treatment of symptomatic venous thromboembolism and, S2:41
  leukocyte binding of, 343
  medium-molecular-weight heparin compared with, 369
  pharmacokinetics and pharmacodynamics of, 343
  in pregnancy, S3:25
  in proliferative vitreoretinopathy, 45
  structural characteristics of, 343
  survival of cancer patients with thromboembolic diseases and, 45
  synthesis of, 343
  for thromboprophylaxis in medical patients, in France, S3:51
  for thrombosis care for medical patients, S3:13
  timing of treatment with, 53
  unresolved issues in venous thromboembolism prevention and treatment and, S2:33
  for venous thromboembolism, review of, S3:3
  venous thromboembolism in cancer patients and, S3:19
  for venous thromboembolism management in Latin American patients, S3:47
  for venous thromboembolism prophylaxis in hospitalized medical patients, 569
Lymphoproliferative disorders, von Willebrand disease with, 227

M
Malignancies. *See also* Metastasis
  antihemostatic agents effects on tumor dissemination and, 29
  onset of, biology of, 67
  surgery for, thromboembolic disease in, rationale for prolonged thromboprophylaxis and, 569
  treatment by activation of plasminogen system, 5
  venous thromboembolism in cancer patients and, S3:19
Medical patients
  hospitalized, risk and prevention of venous thromboembolism in, 577
  thromboprophylaxis in, S3:3
    in France, S3:51
  thrombosis care for, S3:13
Melagatran
  antithrombotic potency of, low molecular weight heparin compared with, 379
  monitoring of anticoagulant effects of thrombin inhibitors and, 361
Melanoma, B16-BL6, inhibition by semisynthetic sulfaminoheparosan sulfates from *E.coli* K5 polysaccharide, 379
Menaquinone, improvement of vitamin K status of breastfeeding infants with maternal supplementation of, 533
Metabolic function, thrombosis and, aging and, 555
Metastasis
  biology of, 67
  coagulation system's role in, 29
  hematogenous phase of, heparin inhibition of selectin-mediated interactions during, 53
  platelets in, 39
  regulation by heparan sulfate-like glycosaminoglycans, 67
Microcirculation, antithrombin attenuation of microvascular leakage and leukocyte-endothelial interaction in response to endotoxin and, S1:87
Monoclonal antibodies, assay of von Willebrand factor-cleaving protease using, 167
Mortality, in cancer, improvement with low molecular weight heparin, 79
Mucins, carcinoma progression and metastasis related to,53
Myeloproliferative disorders, von Willebrand disease with, 227
Myocardial infarction. *See* Coronary syndromes, acute

N
Nematode anticoagulant protein c2, recombinant, S3:33
Neoplasia, von Willebrand disease with, 227
Nutrition, thrombosis and, aging and, 555

O
Oligosaccharides, conformation of heparin tetrasaccharides

bound to fibroblast growth factors and, 325
Oral thrombin inhibitors, S3:33
Orthopedic surgery
optimization of venous thromboembolism prophylaxis and, S2:25
prolonged thromboprophylaxis in, S3:43
Orthotopic liver transplantation, for hepatitis, S1:31
Outpatients, thromboprophylaxis in, in France, S3:51

P
Paget-Schroetter syndrome, 89
Pasteurized clotting factor concentrates
pharmacosurveillance investigation of safety of, in children and adolescents, S1:63
purity, activity, and virus safety of, S1:79
virus-inactivated clotting factor concentrates in severe hemophilia and, S1:75
virus safety of hemophilia treatment using, S1:57
Pediatric patients. *See also* Infants
hepatitis in, S1:31
pharmacosurveillance investigation of safety of pasteurized clotting factor concentrates in, S1:63
recombinant hirudin and danaparoid sodium in, 447
Pentasaccharides
improving outcomes of treatment of symptomatic venous thromboembolism and, S2:41
selective inhibition of coagulation factors and, S2:15
synthetic, selective inhibition of factor Xa by, 393
Percutaneous coronary interventions, hirudin for, 459
Plasma, as starting material for coagulation factor concentrates, S1:25
Plasminogen activator inhibitor-1, increased expression with fibrin deposition in murine model of aging, 545
Plasminogen activators, influence on onset of labor and hemostatic system, 529
Plasminogen system, treatment of malignancies by activation of, 5
Platelet adhesion, mechanism of, S1:33
Platelet counts
to distinguish preeclampsia from normal pregnancy, 495
gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to HELLP syndrome and, 515
high, von Willebrand disease with, 227
perioperative changes in patients undergoing gynecologic surgery, 519
as screening test for von Willebrand disease, 173
Platelet factor 4, inhibition by direct thrombin inhibitors, 379
Platelets
activation of, inhibition by direct thrombin inhibitors, 379
function of, thrombosis and, aging and, 555
inhibition of, 29
in process of metastasis, 53
tumor progression and, 39
von Willebrand factor role in platelet function and, S1:33
Polyacrylamide gel electrophoresis, SDS, analysis of protease-digested von Willebrand factor substrate by, 167
Preeclampsia
association with maternal smoking in Japanese women, 507
coagulation index to distinguish from normal pregnancy, 495
seizures in, anticholinergic induction of, 511
Pregnancy
acute fatty liver of, gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to development of, 515
gestational thrombocytopenia and pregnancy-induced antithrombin deficiency as progenitors to HELLP syndrome and, 515
hemostatic system during, plasminogen activator influence on onset of, 529
heparin-induced thrombocytopenia in, danaparoid for, 439
hypertension prevention in, angiotensinogen gene and body mass index for, 501
low-molecular-weight heparin in, S3:25
with paradoxical brain embolism, 525
preeclampsia and. *See* Preeclampsia
Proliferative vitreoretinopathy, prevention of, 45
Protein C anticoagulant pathway, S2:15
Proteolysis, increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
Prothrombinase-induced clotting time, monitoring of anticoagulant effects of thrombin inhibitors and, 361
Prothrombin levels, in newborn infants, by carinactivase-1 method, 539
Prothrombin time, monitoring of anticoagulant effects of thrombin inhibitors and, 361
Prothrombotic markers, 555
P-selectin glycoprotein ligand-Ig, recombinant, S3:33
Pulmonary disease, thromboprophylaxis in, S3:51
Pulmonary embolism. *See also* Venous thromboembolism
epidemiology of, prevention and management implications of, S2:3
in hospitalized medical patients, risk and prevention of, 577
in surgery for malignancies, rationale for prolonged thromboprophylaxis and, 569
upper extremity deep vein thrombosis and, 89
Pulmonary hypertension, von Willebrand disease with, 227
Purpura. *See* Thrombotic thrombocytopenic purpura

R
Recombinant factor VIII
activity in hemophilia A patients, 257
albumin free, B-domain deleted, preclinical studies of, 269
continuous infusion of, 277
efficacy of, 241, 309
first and second generation
in previously untreated patients, 273, 277
switching patients between, 277
inhibitor development and, 241
pharmacokinetics of, 241
plasma-derived factor VIII versus, in previously untreated patients, 285
in previously treated patients with hemophilia A, 241
production of
advances in, 309
methods for, 277
safety of, 241, 309
during surgery, 277
transmission of infectious disease by, 277
Recombinant hirudin

anti-recombinant hirudin antibodies and, in vitro and in vivo studies of, 483
development of, 405
in pediatric patients, 447
pharmacokinetics of, 467
pharmacology of, 415
in renal insufficiency, 467
Recombinant nematode anticoagulant protein c2, S3:33
Recombinant P-selectin glycoprotein ligand-Ig, S3:33
Renal insufficiency, hirudin in, 467
Ribavirin, for hepatitis C, S1:31
Ristocetin cofactor, von Willebrand factor response to desmopressin and, 111
Ristocetin cofactor activity assay, for von Willebrand factor, 173
collagen-binding assays compared with, 149
reliability of, 149

S

Sclerosis, increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
Seizures, eclamptic, anticholinergic induction of, 511
Selectin, heparin inhibition of interactions mediated by, during hematogenous phase of metastasis, 53
Sialylated fucosylated antigens, metastasis and, 53
Smoking, preeclampsia association with maternal smoking in Japanese women and, 507
SQ-peptides, anti-SQ-peptide specific antibodies in patients treated with ReFacto and, 297
Standards, for factor VIII, 247
product-specific, 257
Stroke, thromboprophylaxis in, S3:51
Sulfaminoheparosan sulfates, semisynthetic, from *E.coli* K5 polysaccharide, B16-BL6 melanoma inhibition by, 379
Sulfation, calcium ion effects on interactions between antithrombin and factor Xa mediated by low molecular weight heparin and, 355
Surgery
gynecologic, perioperative changes in plasma antithrombin activity and platelet counts in patients undergoing, 519
for malignancies, thromboembolic disease in, rationale for prolonged thromboprophylaxis and, 569
orthopedic
optimization of venous thromboembolism prophylaxis and, S2:25
prolonged thromboprophylaxis in, S3:43
perioperative hirudin and, 405
recombinant factor VIII during, 277
venous thromboembolism in cancer patients and, S3:19
venous thromboembolism management in Latin American patients and, S3:47
in von Willebrand disease, Immunate treatment and, 203

T

Thrombin, coagulation activation for glioma treatment and, S1:19
Thrombin-antithrombin complex, to distinguish preeclampsia from normal pregnancy, 495
Thrombin inhibitors
direct, S2:15. *See also* Hirudin
antithrombotic potency of, low molecular weight heparin compared with, 379
monitoring of, methods for, 425
for unstable angina, 459
in glioma treatment, S1:19
monitoring of anticoagulant effects of, 361
oral, S3:33
Thrombocytopenia
gestational, as progenitor to HELLP syndrome, 515
heparin-induced, hirudin for, 405, 431
in pediatric patients, 447
Thrombocytosis
in cancer, 39
reactive, 227
Thrombophilia
congenital, screening for, S3:25
in pregnancy, S3:25
Thrombosis. *See also* Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
aging and, 555
in cancer, 29
increased expression of plasminogen activator inhibitor-1 with fibrin deposition in murine model of aging and, 545
selective inhibition of coagulation factors and, S2:15
Thrombotic thrombocytopenic purpura
in cancer, 39
clinical manifestations of, 167
pathogenesis of, 167
von Willebrand factor-cleaving protease assays for diagnosis of, 167
Tick anticoagulant peptide, S2:15
Tissue factor
coagulation activation for glioma treatment and, S1:19
heparin modulation of, 45
inhibition of, 29
tumor dissemination and, 29
Tissue factor pathway inhibitor, S2:15, 29
Tissue-type plasminogen activator, influence on onset of labor and hemostatic system, 529
Total joint arthroplasty, prolonged thromboprophylaxis in, S3:43
Transfusion, virus transmission during hemophilia treatment and, S1:31
Tree-based analysis, of lifestyle risks for hypertension in pregnancy, 501
Trousseau's syndrome, association with mucin-producing carcinomas, 53
Tumor growth
anticoagulant interference with, 45
biology of, 67
regulation by heparan sulfate-like glycosaminoglycans, 67
Tyramine, low molecular weight heparin and dermatan sulfate labeled with, study of biological functions and pharmacology using, 343

U

Unstable angina

antiplatelet drugs for, S3:3
direct thrombin inhibitors in, 459
Upper extremity, deep vein thrombosis of, 89
Urinary plasminogen activator, influence on onset of labor and hemostatic system, 529
Ursodeoxycholic acid, for hepatitis C, S1:31

V
Vaccination, virus safety of hemophilia treatment and, S1:31
Vascular endothelial growth factor, heparin binding to, 45
Vasospasm, eclamptic seizures and, 511
Venous stasis syndrome, as venous thromboembolism complication, S2:3
Venous thromboembolism. *See also* Deep vein thrombosis; Pulmonary embolism
in cancer, S3:19, 39
complications of, S2:3
epidemiology of, prevention and management implications of, S2:3
in hospitalized medical patients, risk and prevention of, 577
management of
anticoagulants and survival and, 45
benefits of selective factor inhibition for, S2:49
conclusions regarding, S3:57
future challenges for, S3:33
improving outcomes of treatment of symptomatic disease and, S2:41
in Latin American patients, S3:47
in medical patients, S3:13
in outpatients, S3:3
real-world, critical assessment of, S3:41
transfusion therapy for, review of, S3:3
uncharted territories in, S3:1
unresolved issues in, S2:33
perioperative changes in plasma antithrombin activity and platelet counts in patients undergoing gynecologic surgery and, 519
in pregnancy, low molecular weight heparin and, S3:25
prevention of
in hospitalized medical patients, 577
optimization of, S2:25
in outpatients, S3:3
prolonged thromboprophylaxis in orthopedic surgery and, S3:43
unresolved issues in, S2:33
recurrence of, S2:3
prevention of, S3:3
risk factors for, S3:33
in surgery for malignancies, rationale for prolonged thromboprophylaxis and, 569
symptomatic, improving outcomes of treatment of, S2:41
Venous ulcers, as venous thromboembolism complication, S2:3
Virus safety of hemophilia treatment
antithrombin attenuation of microvascular leakage and leukocyte-endothelial interaction in response to endotoxin and, S1:87
in Germany and Austria, review of past 15 years of, S1:9
greetings from German Hemophilia Society of Gesellschaft für Thrombose- und Hämostaseforschung and, S1:7
hepatitis viruses and. *See* Hepatitis viruses
infectious and noninfectious side effects during cryoprecipitate treatment and, S1:51
of pasteurized antithrombin concentrate, S1:79
pasteurized clotting factor concentrates and, S1:57
in children and adolescents, S1:63
starting material and, S1:25
status of infection in young hemophilia patients in Münster and, S1:47
symposium in honor of Norbert Heimburger on his 70th birthday and, S1:5
tribute to Norbert Heimburger and, S1:1
virus-inactivated clotting factor concentrates in severe hemophilia and, S1:75
virus-safe blood coagulation factor concentrates for, S1:15
Vitamin K
antagonists of, metastasis and, 53
improvement of vitamin K status of breastfeeding infants with maternal supplementation of vitamin K2 and, 533
prothrombin levels by carinactivase-1 method in newborn infants and, 539
Vitreoretinopathy, proliferative, prevention of, 45
von Willebrand disease
acquired, 227
clinical manifestations of, 173
congenital, laboratory diagnosis of, 173
epidemiology of, 173
Immunate treatment of, 203
underdiagnosis of, 227
von Willebrand factor
collagen-binding assays for, 173
comparison of, 139
experience with, 191
for quantitation of proteolysis, 167
ristocetin cofactor activity assay compared with, 149
enzyme-linked immunosorbent assay of, 139
proteolytic degradation of, 167
qualitative deficiency of, 173
quantitative deficiency of, 173
recombinant, animal studies of, 215
response to desmopressin, in patients with type 1 and type 2 congenital von Willebrand disease, 111
ristocetin cofactor activity assay for, 173
reliability of, 149
role in platelet function, S1:33
von Willebrand factor-cleaving protease, assays of, for thrombotic thrombocytopenic purpura diagnosis, 167
von Willebrand factor:multimer assay, 191

W
Warfarin, S2:15
effects on tumor dissemination, 29
in pregnancy, S3:25
survival of cancer patients with thromboembolic diseases and, 45